Personalized PSMA radioligand treatment for advanced prostate cancer
Enhancing radioligand therapy for prostate cancer with biomarker and dosimetry guided personalization
This project aims to personalize PSMA-targeted radioligand therapy using imaging and blood or bone marrow markers to give safer, more effective radiation for men with advanced prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11193875 on NIH RePORTER |
What this research studies
If you join, you'll get detailed PSMA-PET and SPECT imaging before and during treatment so doctors can see how much radiation reaches tumors and organs. Clinicians will combine those images with biomarker tests and bone marrow checks to tailor the radioactivity given each cycle, potentially giving a higher first dose and adjusting later doses. Blood counts and organ function will be monitored closely to limit bone marrow and other toxicities. Treatments will use FDA‑approved 177Lu‑PSMA therapy but with individualized dosing guided by dosimetry and biomarkers.
Who could benefit from this research
Good fit: Ideal candidates are men with metastatic castration‑resistant prostate cancer who are eligible for 177Lu‑PSMA therapy and have PSMA-positive scans.
Not a fit: People whose tumors do not show PSMA on PET, those with earlier-stage prostate cancer who do not need radioligand therapy, or patients unable to undergo required imaging or follow-up are unlikely to benefit.
Why it matters
Potential benefit: If successful, this approach could deliver more radiation to tumors while protecting bone marrow and other organs, improving cancer control and reducing side effects.
How similar studies have performed: Fixed-dose 177Lu‑PSMA therapy has shown clinical benefit and regulatory approval, but imaging- and biomarker-guided dosimetry personalization is a newer strategy that has not yet been proven in large trials.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Dewaraja, Yuni K — University of Michigan at Ann Arbor
- Study coordinator: Dewaraja, Yuni K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.